Nerdwallet Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? Nerdwallet Inc trades at $9.91 (market cap $625.17M), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 39.5× Nerdwallet Inc's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| NRDS | ROIV | |
|---|---|---|
Market Cap | $625.17M | $24.72B |
Volume | 1,321,316 | 6,279,442 |
Sector | Media | Health |
52-Week High | $15.93 | $41.81 |
52-Week Low | $7.58 | $16.04 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $539.47M | $20.99B |
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.085, up 2.54% with bullish technical indicators and strong fundamental momentum. The company shows impressive revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive to $48.7M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, but Q1 and Q4 2025 beat estimates. Analyst consensus remains positive with 4 buy ratings out of 6, and technical analysis shows bullish signals across moving averages and oscillators.
Outlook remains favorable with projected 2026 revenue of $860M and net income of $65M, though Q2 earnings miss and high RSI suggest near-term caution. The stock offers attractive valuation with P/E of 10.87 and P/S of 0.81, but faces risks from organic search pressure in key product categories and macroeconomic sensitivity.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →